Clinical Trials Logo

SCLC clinical trials

View clinical trials related to SCLC.

Filter by:

NCT ID: NCT01797159 Completed - Clinical trials for Small-cell Lung Cancer

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

Start date: March 11, 2013
Phase: N/A
Study type: Interventional

The Investigators are looking to compare standard treatment for the management of small cell lung cancer (SCLC) which is prophylactic cranial Irradiation (PCI) (shown to be very good in patient survival) with cranial sparing PCI. Although standard of care PCI is successful in patient survival it also has neurologic side-effects. The Investigators are hoping the cranial sparing PCI has the same positive survival results with the added benefit of lowering neurological side-effects.

NCT ID: NCT01713296 Completed - SCLC Clinical Trials

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

Start date: November 2011
Phase: Phase 2
Study type: Interventional

Investigators propose to study the single agent activity of pazopanib in a Phase II trial of patients with relapsed or refractory small cell lung cancer. Because these patients have very limited treatment options, use of an investigational agent in this patient population is supported by current National Comprehensive Cancer Network guidelines. Using correlative biologic studies to evaluate the anti angiogenic activity of pazopanib in the absence of concomitant chemotherapy will allow us to delineate the responses due to this drug and the effect on angiogenesis. Pazopanib dose has been determined to 800 mg once daily per the initial recommended dose approved by FDA and EMA, as monotherapy in advanced Renal Cell Carcinoma

NCT ID: NCT01253369 Completed - Lung Cancer Clinical Trials

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Pazopanib is a drug that inhibits proteins thought to be important for new blood vessel formation. This drug has been used in other cancer research studies and information from those studies suggests that pazopanib may help block proteins that are important for the growth, invasion, and spread of cancer cells.

NCT ID: NCT00522639 Terminated - Lung Cancer Clinical Trials

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation

FDG-PET lung
Start date: October 2008
Phase: Phase 3
Study type: Interventional

The objective of the study is to investigate the evolution ofn 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with lung cancer of during and after concurrent radiotherapy and chemotherapy

NCT ID: NCT00447421 Terminated - Clinical trials for Small Cell Lung Cancer

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.

NCT ID: NCT00346385 Completed - Ovarian Cancer Clinical Trials

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Start date: March 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.

NCT ID: NCT00046787 Completed - SCLC Clinical Trials

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

Start date: September 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.